The global market for the treatment of erectile dysfunction and premature ejaculation is estimated to be around USD 7.5 billion in 2023. The market is expected to grow by over 50% from 2022 to 2029.
The most common drugs used to treat erectile dysfunction, PDE5 inhibitors, which include Viagra, were revolutionary when they first arrived on the market in the late 1990s, but they have their limitations, and the market has evolved since then. There is a clear need for new pharmaceuticals that provide a longer lasting effect, fewer side effects and that provide treatment to those patients that are not currently helped by PDE5 inhibitors.
There are today few effective treatments for premature ejaculation introduced to the market.
Dicot's drug candidate is intended to be marketed towards the treatment of both dysfunctions, both separately and in combination. As far as Dicot is aware, simultaneous treatment of both conditions would be unique.